News | October 29, 2010

LAA Occluder System CE Mark Study Launched


The first-in-man use of the Coherex WaveCrest left atrial appendage (LAA) occluder system was successfully performed recently in New Zealand, launching the WAVECREST 1 trial to evaluate the device's effectiveness. The trial is being carried out in New Zealand, Australia and several European countries and will be used to seek CE mark approval for the device.

The first procedure was performed at Auckland City Hospital in New Zealand by Peter Ruygrok, M.D.

“The Coherex WaveCrest system is a significant advance in LAA occlusion technology,” Ruygrok said. “It offers several major advantages over early LAA devices. It enabled us to optimize the placement of the implant and to seal off the LAA, while minimizing the risk of complications during and after the procedure. The first implantation of this device was extremely successful. WaveCrest presents a valuable new treatment option for patients who suffer from atrial fibrillation and the associated risks of stroke, and possibly enables patients to discontinue difficult-to-manage blood thinners such as Coumadin. This particular patient was at high risk for recurrent stroke, and the structure of the LAA was quite complicated. Nevertheless, the Coherex WaveCrest performed beautifully and our patient is doing quite well.”

Coherex Medical is currently in discussions with the U.S. Food and Drug Administration (FDA) regarding the design of a pivotal trial that may lead to U.S. clearance for the Coherex WaveCrest. The company expects to begin the FDA trial sometime in late 2011.

The LAA is a small pouch-like structure found in every human heart and known as a potential breeding ground for blood clots in patients with atrial fibrillation. It is believed to cause 15 percent of all strokes.

For more information: www.coherex.com


Related Content

Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home June 12, 2024
Home
News | Cardiovascular Clinical Studies

June 6, 2024 —Cleveland Clinic researchers found higher amounts of the sugar alcohol xylitol are associated with ...

Home June 06, 2024
Home
News | Cardiovascular Clinical Studies

May 31, 2024 — CareDx, a leading precision medicine company focused on the discovery, development, and commercialization ...

Home May 31, 2024
Home
News | Cardiovascular Clinical Studies

May 29, 2024 — Data was presented by AstraZeneca on AZD0780, an oral PCSK9 inhibitor which demonstrated significant LDL ...

Home May 29, 2024
Home
News | Cardiovascular Clinical Studies

May 23, 2024 — A newly-published peer-reviewed study in the Journal of the American Heart Association, JAHA, found that ...

Home May 23, 2024
Home
News | Cardiovascular Clinical Studies

May 23, 2024 — Global Heart Hub, the international alliance of heart patient organizations, announced the first findings ...

Home May 23, 2024
Home
News | Cardiovascular Clinical Studies

May 21, 2024 — A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging ...

Home May 21, 2024
Home
News | Cardiovascular Clinical Studies

May 20, 2024 — Cardiologist Brendan Carry, MD, and a team of Danville, PA-based Geisinger Medical Center physicians have ...

Home May 20, 2024
Home
News | Cardiovascular Clinical Studies

May 18, 2024 — Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ...

Home May 18, 2024
Home
Subscribe Now